









Markets
/
Stocks
/
nasdaq-vstm
/

Verastem Inc

VSTM

8.070USD

+0.140+1.77%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

538.66MMarket Cap

LossP/E TTM



Verastem Inc

8.070

+0.140+1.77%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Verastem Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Verastem Inc's Score

Industry at a Glance

Industry Ranking

95 / 407

Overall Ranking

218 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

16.000

Target Price

+98.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Verastem Inc Highlights

StrengthsRisks

Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 285.21% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.00M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 10.00M.

Fairly Valued

The company’s latest PE is -1.88, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 53.21M shares, decreasing 3.45% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 3.34M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.20.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 5.99, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.99

Change



Financials

6.85

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.05

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.35

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Verastem Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 5.76, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -1.88, which is -64.06% below the recent high of -0.68 and -88.57% above the recent low of -3.55.

Score

Industry at a Glance

Previous score

5.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 95/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Verastem Inc is 15.50, with a high of 20.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

16.000

Target Price

+98.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Verastem Inc

VSTM

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 7.05, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 9.78 and the support level at 6.67, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.99

Change

0.06

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.142

Sell

RSI(14)

44.211

Neutral

STOCH(KDJ)(9,3,3)

23.525

Sell

ATR(14)

0.706

High Vlolatility

CCI(14)

-70.712

Neutral

Williams %R

79.528

Sell

TRIX(12,20)

-0.162

Sell

StochRSI(14)

10.370

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

8.394

Sell

MA10

8.702

Sell

MA20

8.654

Sell

MA50

9.024

Sell

MA100

7.563

Buy

MA200

6.970

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 86.71%, representing a quarter-over-quarter increase of 5.88%. The largest institutional shareholder is The Vanguard, holding a total of 3.42M shares, representing 5.56% of shares outstanding, with 7.11% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RTW Investments L.P.

4.25M

+0.14%

Balyasny Asset Management LP

4.21M

-12.16%

The Vanguard Group, Inc.

Star Investors

3.42M

+40.88%

Logos Global Management LP

3.42M

+242.50%

Point72 Asset Management, L.P.

Star Investors

3.34M

Foresite Capital Management, LLC

1.28M

Nantahala Capital Management, LLC

2.95M

+28.55%

BlackRock Institutional Trust Company, N.A.

2.49M

+6.92%

J. Goldman & Co., L.P.

2.45M

+1284.88%

State Street Investment Management (US)

2.25M

+177.22%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.36, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.